Compare FMC Corp (FMC) vs Okta, Inc. (OKTA) Price & Performance

FMC Corporation (FMC) trades at $11.61, up 8.3% today, but remains in a challenging fundamental position with a net income margin of -72.93% and negative ROE of -80.78% for 2025. The company is actively restructuring, securing a $400 million minority investment from Tessenderlo Group and planning a $114 million property sale to reduce its $3.03 billion long-term debt. Technical indicators are bearish, with the stock trading near key support at $11. Recent news highlights progress on its new herbicide, rimisoxafen, including a regulatory submission to the EPA and a partnership with Corteva.

The outlook is cautious. While aggressive debt reduction and new product pipelines offer potential, deep losses and declining revenue pose significant risks. The analyst consensus is mixed (47.6% Buy, 50% Hold) with a $16 price target, suggesting modest upside if turnaround efforts succeed, but high execution risk remains the primary concern for investors.

OKTA trades at $150.97, down 2.36% on the day, with a bullish technical outlook supported by moving averages and strong institutional interest. The company reported revenue of $2.61B in 2025, achieving positive net income of $28M after years of losses, and has beaten earnings estimates for three consecutive quarters. Analyst consensus is strongly bullish with 72.55% buy ratings, though the stock trades above the consensus price target of $125.78.

The outlook for OKTA is positive due to robust revenue growth, improving profitability, and strong demand for AI-driven cybersecurity solutions. Key risks include high valuation multiples, intense competition, and sensitivity to enterprise IT spending cycles. The stock presents a growth opportunity but requires monitoring of execution and market sentiment shifts.